Abstract:Objective To evaluate the efficacy and safety of phenylalanine-free amino acid-based formula (AA-PKU1) in the treatment of Chinese infants with phenylketonuria (PKU).Methods The prospective,open,selfcontrolled,multi-center trial was performed with a 32-week treatment period with recommended AA-PKU1 intake 20 g/(kg body weight · day).Each subject served as his/her own control and the values in treatment after 8 weeks and 32 weeks were compared to baseline.Total 39 PKU infants aged 0-4 months were enrolled in the study.The blood phenylalanine (PHE) level,developmental quotient (DQ),weight,height and head circumferences and nutritional biomarkers [total protein (TP),pre-albumin (Pre-Alb),albumin (Alb),total cholesterol (TC),total triglyceride (TG),low-density lipoprotein cholesterol (LDL-C),high-density lipoprotein cholesterol (HDL-C)] were measured in baseline,after 8 weeks and 32 weeks,respectively.The routine blood & urine examination and the renal & hepatic function examinations were also conducted in baseline,after week 8 and week 32 with adverse events and adverse reactions observed during treatment.Results Three subjects dropped out,36 subjects entered the per protocol set with the statistical analysis of efficacy conducted and 39 subjects entered the safety set with the statistical analysis of safety conducted during treat ment after week 8.Five subjects dropped out,34 subjects entered the per protocol set with the statistical analysis of efficacy conducted and 39 subjects entered the safety set with the statistical analysis of safety conducted during treatment after week 32.The mean blood PHE level in the treatment of week 8 and week 32 were 196.0 μmol/L and 191.1μmol/L,respectively.Statistically significant differences were found between pre-treat PHE level(649.5 μmol/L) and post-treat PHE level(P ＜ 0.000 1).The PHE control rates in week 8 and week 32 were 88.89％ and 88.24％,respectively(the PHE control level ＜ 360 μmol/L).The DQ scores in 5 function areas (adaptive behavior,gross motor,fine motor,language and personal-social behavior) in week 8 and week 32 were similar to baseline.The height,weight and head circumferences in week 8 and week 32 increased significantly compared with baseline (all P ＜ O.000 1).The mean values of TP,Pre-Alb,Alb,TC,TG,LDL-C and HDL-C in week 8 and week 32 were close to baseline within the normal range.The drug-related adverse events(so-called:adverse drug reactions) occurred 14 times in 10 cases (8 cases of diarrhea,1 case of vomiting and 1 case of diarrhea with vomiting) with mild to moderate severity.All these symptoms could either relieve themselves or disappear with symptomatic treatment.Conclusions AA-PKU1 can effectively maintain the ideal blood PHE level and normal intelligence development,and can fulfill normal growth needs and improve the nutritional condition for PKU infants.AA-PKU1 feeding was also safe and well tolerated for PKU infants.

Progress in Intelligence,Congnitive Function and Behaviour of Children with Phenylketonuria

The Behavioral and Emotional Problems of Patients with Phenylketonuria Early Treated with Dietotherapy

Mental and motor development and psychosocial adjustment of Chinese children with phenylketonuria.

Advanced research in newborn screening and diagnosis methods of phenylketonuria

Pitfalls in the Management of Phenylketonuria in China

Efficacy and Safety of a Phenylalanine-Free Amino Acid-Based Enteral Formula (AA-PKU2) in 1-8 Year-Old Children with Phenylketonuria: a Prospective, Open, Self-Controlled and Multi-Center Study in China

Efficacy and Safety of Phenylalanine-Free Amino Acid-Based Formula(aa-Pku1) on Chinese Infants with Phenylketonuria

Long-term Follow-Up of Children with Carbamoyl Phosphate Synthase 1 Deficiency Detected in Newborn Screening.

Advances in research of molecular mechanism of phenylketonuria and its treatments

Analysis of Phenylketonuria in 39 Children

Association between Iron Deficiency in Early Development and Alterations in Behavior Pattern and Regional Brain Dopaminergic Function

[Brain White Matter Lesions of Children with Phenylketonuria Before and after Treatment].

[An Eighteen-Year Study on Phenylketonuria].

Screening for Hereditary Tyrosinemia and Genotype Analysis in Newborns

[Psychomotor Retardation and Intermitent Convulsions for 8 Months in an Infant].

Neurocognitive outcome and mental health in children with Tyrosinemia type 1 and Phenylketonuria: A comparison between two genetic disorders affecting the same metabolic pathway

Investigation and Status of Dietary Therapy and Nursing at Home of Phenylketonurics Children

No Impairment in Bone Turnover or Executive Functions in Well-Treated Preschoolers with Phenylketonuria-A Pilot Study

Emotional and behavioural functioning in children with tyrosinaemia type 1

Study on brain delayed myelination and blood phenylalanine of patients with phenylketonuria

Executive functions & metabolic control in phenylketonuria (PKU) and mild hyperphenylalaninemia (mHPA)